The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments

Archiv der Pharmazie

Volumn 339, Issue 7, 2006, Pages 346-355

  Keller, Paul A ^a   McCluskey, Adam ^b   Morgan, Jody ^a   O'Connor, Sean M J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Corticotrophin releasing factor; Psychiatric disorders; Therapeutics

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DEXAMETHASONE; GLUCOCORTICOID; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; AUTOPSY; BLURRED VISION; CEREBROSPINAL FLUID; CONSTIPATION; CONVULSION; DEPRESSION; DROWSINESS; FATIGUE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LIBIDO DISORDER; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVIEW; STRESS; SUBSTANCE ABUSE; TREMOR;

AMINO ACID SEQUENCE; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MENTAL DISORDERS; MOLECULAR SEQUENCE DATA; PITUITARY-ADRENAL SYSTEM; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 33747055579     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200600021     Document Type: Review

References (65)

1. D. A. Regier, W. E. Narrow, D. S. Rae, R. W. Manderscheid, et al. Arch. Gen. Psychiat. 1993, 50, 85-94.
2. The Numbers Count: Mental Disorders in America, http://www.nimh.nih.gov/ publicat/numbers.cfm (28/3/2006).
3. Social Inequalities and the Distribution of the Common Mental Disorders (Ed.: T. Fryers, R. Jenkins, D. Melzer), 2nd edition, Taylor & Francis, New York, 2004.
4. A. J. Mitchell, Neurosci. Biobehav. Rev. 1998, 22, 635-651.
5. M. Pelleymounter, M. Joppa, M. Carmouche, M. J. Cullen, et al., J. Pharm. Exp. Ther. 2000, 293, 799-806.
6. T. W. Lovenberg, D. T. Chalmers, L. Changlu, E. B. De Souza, Endocrinology 1995, 136, 4139-4142.
7. R. L. Leahy, S. J. Holland, Treatment Plans and Interventions for Depression and Anxiety Disorders, 1st edition, The Guilford Press, New York, 2000.
8. D. K. Grammatopoulos, G. P. Chrousos, Trends Endocrin. Metab. 2002, 13, 436-444.
9. S. M. Stahl, Essential Psychopharmacology, 3rd edition, Cambridge University Press, Cambridge, 1998.
10. K. Lambert, C. H. Kinsley, Clinical Neuroscience, 1st edition, Worth Publishers: New York, 2004.
11. M. Townsend, Essentials of Psychiatric Mental Health Nursing. 3rd edition, F. A. Davis, Philadelphia, 2005.
12. Z. Sarnyai, Y. Shaham, S. C. Heinrichs, Pharmacol. Rev. 2001, 53, 209-243.
13. N. R. Carlon, Foundations of Physiological Psychology, 6th edition, Pearson Education, Boston, 2005.
14. G. Baker, W. Dewhurst, Biochemical Theories of Affective Disorders, 2nd edition, Croom Helm, London, 1985.
15. C. B. Nemeroff, Sci. Am. 1998, 278, 28-35.
16. H. Rang, M. Dale, J. Ritter, P. K. Moore, Pharmacology, 5th edition, Churchill Livingstone, Loanhead, 2003.
17. A. Frazer, J. Clin. Psychopharm. 1997, 17, Suppl 1, 2S-18S.
18. M. Wong, J. Licinio, Nat. Rev. Neurosci. 2001, 2, 343-351.
19. A. Savinelli, Multidisciplinary Association for Psychedelic Studies Letters 1995, 6, 58.
20. R. Pies, J. Clin. Psychopharm. 1995, 15, 303-305.
21. I. Maidment, Psychiatr. Bull. 2000, 24, 348-351.
22. C. Salzman, J. Psychiat. Res. 1993, 27, Suppl 1, 97-110.
23. B. DeSouza, D. Grigoriadis, Neuropsycopharmacology: The Fifth Generation progress, 5th edition, 2002, p. 19.
24. M. P. Conn, H. M. Goodman, A. Cherrington, L. S. Jefferson, J. L. Kostyo, The Endocrine System, 1st edition, Oxford University Press, New York, 2001.
25. D. K. Grammatapoulos, E. W. Hillhouse, Lancet 1999, 354, 1546-1549.
26. G. Aguilera, M. A. Millan, R. L. Hauger, Annal. NY Acad. Sci. 1987, 512, 48-66.
27. E. Ur, A. Grossman, Acta Endocrinol. 1992, 127, 193-199.
28. T. L. Bale, W. W. Vale, Ann. Rev. Pharmacol. 2004, 44, 525-557.
29. P. J. Gilligan, D. W. Robertson, R. C. Zaczek, J. Med. Chem. 2000, 43, 1641-1660.
30. E. B. DeSouza, J. Neurosci. 1987, 7, 88-100.
31. D. E. Grigoriadis, X. J. Liu, J. Vaughn, Mol. Pharmacol. 1996, 50, 679-686.
32. E. B. DeSouza, E. L. Webster, D. E. Grigoriadis, D. E. Tracey, Psychopharmacol. Bull. 1989, 25, 299-305.
33. F. Holsboer, J. Psychiat. Res. 1998, 33, 181-214.
34. D. N. Orth, Endocr. Rev. 1992, 13, 164-191.
35. S. P. Malkoski, R. I. Dorin, Mol. Endocrinol 1999, 13, 1629-1644.
36. M. J. Perone, C. A. Murray, O. A. Brown, S. Gibson, et al., Mol. Cell Endocrinol. 1998, 142, 191-202.
37. G. Aguilera, Trends Endocrin. Met. 1998, 9, 329-336.
38. E. J. Nestler, M. Barrot, R. J. Di Leone, A. J. Eisch, et al., Neuron 2002, 34, 13-25.
39. H. Lehnert, C. Schulz, K. Dieterich, Neurochem. Res. 1998, 23, 1039-1052.
40. K. Itoi, A. F. Seasholtz, S. J. Watson, Endocrinol. J. 1998, 45, 13-33.
41. M. J. Owens, C. B. Nemeroff, Pharmacol Rev. 1991, 43, 425-473.
42. C. B. Nemeroff, G. Bissette, A. C. Andorn, M. Stanley, Arch. Gen. Psychiatry. 1988, 45, 577-579.
43. F. C. Raadsheer, W. J. Hoogendijk, F. C. Stam, F. J. Tilders, D. F. Swaab, Neuroendocrinology 1994, 60, 436-444.
44. F. Raadasheer, K. Heerikhuize, J. Lucassen, W. Hoogendijk, et al. Am. J. Psychiat. 1995, 152, 1372-1376.
45. C. M. Banki, L. Karmacsi, G. Bissette, C. B. Nemeroff, J. Affect. Disorders 1992, 25, 39-45.
46. C. B. Nemeroff, G. Bissette, H. Walleus, I. Karlsson, et al., Science 1984, 226, 1342-1344.
47. L. Arborelius, M. J. Owens, P. M. Plotsky, C. B. Nemeroff, J. Endocrinol 1999, 160, 1-12.
48. F. Holsboer, A. Gerken, U. von Bardekeben, W. Grimm, et al., Biol Psychiatry 1986, 21, 601-611.
49. F. Holsboer, C. J. Lauer, W. Schreiber, J.-L. Krieg, Neuroendocrinology 1995, 62, 340-347.
50. M. Joels, E. R. de Kloet, Prag. NeuroUol. 1994, 43, 1-36.
51. K. Inoue, G. R. Valdez, T. M. Reyes, L. E. Reinhardt, et al., J. Pharmacol. Exp. Ther. 2003, 305, 385-393.
52. M. A. Pelleymounter, M. Joppa, M. Carmouche, M. J. Cullen, et al. J. Pharmacol. Exp. Ther. 2000, 293, 799-806.
53. T. Skutella, J. C. Probst, U. Renner, F. Holsboer, C. Behl, Neuroscience 1998, 85, 795-805.
54. S. Aston-Jones, G. Aston-Jones, G. F. Koob, Psychopharmacology 1984, 84, 28-31.
55. H. A. Baldwin, S. Rassnick, J. Rivier, G. F. Koob, K. T. Britton, Psychopharmacology 1991, 103, 227-232.
56. M. E. Carroll, R. A. Meisch, Adv. Behav. Pharmacol. 1984, 4, 47-88.
57. P. A. Iredale, J. D. Alvaro, Y. Lee, R. Z. Terwillinger, et al., J. Neurochem. 2000, 74, 199-208.
58. A. McClusky, J. Garner, P. A. Keller, Bioorg. Med. Chem. 2000, 8, 1213-1223.
59. M. Lanier, J. P. Williams, Expert Opin. Ther. Pat. 2002, 12, 1619-1630.
60. C. Contoreggi, K. C. Rice, G. Chrousos, Neuroendocrinology 2004, 80, 111-123.
61. D. Grigoriadis, M. Haddach, N. Ling, J. Saunders, Curr. Med. Chem. - CNS Agents 2001, 1, 63-97.
62. D. W. Shulz, R. S. Mansbach, J. Sprouse, J. P. Braselton, et al., Proc. Natl. Acad. Sci. USA 1996, 93, 10477-10482.
63. A. W. Zobel, T. Nickel, H. E. Kunzel, N. Ackl, et al., J. Psychiatry Res. 2000, 34, 171-181.
64. D. A. Gutman, M. J. Owens, K. H. Skelton, K. V. Thrivikraman, C. B. Nemeroff, J. Pharmacol. Exp. Ther. 2003, 304, 874-880.
65. C. F. Gillespie, C. B. Nemeroff, Psychosom. Med. 2005, 67, Suppll, S26-S28.